Blastic plasmacytoid dendritic cell neoplasm
ICD-10 C85.7 · ICD-11 2A60.5

Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Young, Fit Patients Eligible for Allogeneic Stem Cell Transplantation

Clinical Scenario
Young age Fit AlloSCT candidate

For the few young and fit patients who are considered allogeneic stem cell transplantation (alloSCT) candidates, the aim is to achieve complete remission prior to alloSCT.

Treatment Approach

Induction therapy — with either a targeted agent or intensive chemotherapy — is employed to achieve complete remission before proceeding to allogeneic transplantation.

Response Goals (Complete Remission)
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.6004/jnccn.2023.7026

For the few young and fit patients who are considered alloSCT candidates, the aim is to achieve complete remission (CR) prior to alloSCT.

Prior to December 2018, management of BPDCN revolved around intensive chemotherapy utilizing AML (7+3 [7 days of cytarabine + 3 days of either daunorubicin or idarubicin]) or ALL/B-cell lymphoma (HCVAD [hyperfractionated cyclophosphamide/vincristine/doxorubicin/dexamethasone] or CHOP [cyclophosphamide/doxorubicin/vincristine/prednisone]) regimens.

In this trial, Pemmaraju et al first described in detail the clinical response criteria for BPDCN: normalization of peripheral blood counts; bone marrow blasts (<5%); regression of nodal, spleen, and liver masses; and 100% clearance of all skin lesions with no new lesions.

View source ↗